Checked.be
Active
BE 0805.162.158Public limited company
OncoRNA
Rue Louis Breguet 1 ·6041 Charleroi, Belgium· 2 yrs active
Sector: Speur- en ontwikkelingswerk op biotechnologisch gebied
(72101)
Conclusion
The computed 12-month bankruptcy probability of OncoRNA is 2.1% (moderate). The 2024 annual accounts show negative equity (€-16k) and a net result of €-38k. Its solvency ranks better than 10% of 174 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 2 annual accounts.
Key figures
| Equity | €-16k |
| Net result | €-38k |
| Better than sector | 10% |
| Active | 2 yrs |
Snowflake analysis
60
/ 100
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
Health
25
Profitability
100
Solvency
33
Growth
58
Stability
82
Bankruptcy probability (12 mo)
2.1%
Moderate
0%0,5%1,5%4%10%≥25%
Annual accounts: weaker financial profile
+Young company
+Lower-failure-rate sector
−
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Risk Assessment
0 / 100
Low riskTrust signals
Young company
Founded in 2023, under 3 years, statistically higher risk.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Health barometer
25
/ 100
Weak
Computed from 4 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.
Financial overview
Annual accounts filed on 30-07-2025 with the NBB · fiscal year 2024 · micro
Sector comparison
Fiscal year 2024 · NACE 72 · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -98.1% | 55.0% | |
| Net result | €-38k | €16k | |
| Equity | €-16k | €70k | |
| Gross operating margin | €-36k | €41k | |
| Staff costs | €1k | €58k |
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
€-38k
+3.2%
23-24
€17k
-40.4%
23-24
€-16k
-
23-24
€-16k
-
23-24
€1k
-
23-24
€33k
+461.7%
23-24
€33k
+461.7%
23-24
0.50
-89.4%
23-24
0.50
-89.4%
23-24
-98.1%
-
23-24
-2.02
-
23-24
235.0%
-
23-24
-230.6%
-62.4%
23-24
Figures by fiscal year
| Fiscal year | 2024 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | - |
| Net profit | €-38k |
| Cash flow | - |
| Staff costs | €1k |
| Income taxes | - |
| Dividends | - |
| Total assets | €17k |
| Equity | €-16k |
| Debt | €33k |
| of which ≤ 1y | €33k |
| of which > 1y | - |
| Working capital | €-16k |
| Employees (FTE) | - |
Ratios (computed)
| 2024 | |
|---|---|
| Current ratio | 0.50 |
| Quick ratio | 0.50 |
| Working capital ratio | -98.1% |
| Solvency | -98.1% |
| Debt / equity | -2.02 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | -230.6% |
| ROE | 235.0% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €17k |
| Current assets | 29/58 | €17k |
| Amounts receivable within one year | 40/41 | €2k |
| Cash & bank | 54/58 | €15k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €17k |
| Equity | 10/15 | €-16k |
| Contributions / capital | 10/11 | €62k |
| Accumulated profits (losses) | 14 | €-78k |
| Amounts payable | 17/49 | €33k |
| Amounts payable within one year | 42/48 | €33k |
| Trade debts payable within one year | 44 | €6k |
| Income statement | ||
| Gross operating margin | 9900 | €-36k |
| Operating result | 9901 | €-38k |
| Financial charges | 65 | €454 |
| Result before taxes | 9903 | €-38k |
| Net result for the period | 9904 | €-38k |
| Result to be appropriated | 9905 | €-38k |
You are seeing the latest fiscal year only. 1 prior year (figures + ratios) is in a paid plan.
See plans →
Ratios computed by Checked.
Legal Structure
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Public limited company(014) |
| Incorporation | 28-08-2023 |
| Status | Active |
| Postal code | 6041 |
Establishment units
OncoRNA
since 20232.348.914.881
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Updates
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
2025
30-07-2025
NBB filing
Annual accounts filed
2024
04-10-2024
NBB filing
Annual accounts filed
Credit advice
Company registry (CBE)
Activities
Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen21201Vervaardiging van overige farmaceutische producten21209Vervaardiging van overige farmaceutische producten21209
Primary activity highlighted.
Names & trade names
| Legal nameFR | OncoRNA |
Registered office
Rue Louis Breguet 1
6041 Charleroi, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies
BMRF Consult
BE 0800.619.588 · Trooz
NCD Consultants
BE 1006.681.242 · Overijse
Bio-Based Business Ecosysteem Transformator
BE 0792.384.585 · Herk-de-Stad
Greenewable Consulting & Management
BE 0797.048.505 · Seraing
Yagh Penn Consulting
BE 0762.771.376 · Bertem